EWM
ARRY

Edge Wealth Management’s Array Biopharma Inc ARRY Stock Holding History

Edge Wealth Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,000
Closed -$185K – 583
2017
Q3 		$185K Buy
+15,000
New +$139K 0.06% 128

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Edge Wealth Management's ARRY Position: Q4 2017 in Review

Edge Wealth Management sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 15,000 shares — an estimated $185K sold.

Edge Wealth Management first reported a position in ARRY in Q3 2017 and held it in 1 quarter. The position peaked at $185K in Q3 2017. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

  • Edge Wealth Management reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
  • Edge Wealth Management sold 15,000 Array Biopharma Inc shares in Q4 2017, an estimated $185K.
  • Edge Wealth Management first reported a position in Array Biopharma Inc in Q3 2017 and held it in 1 quarter.
  • Edge Wealth Management's Array Biopharma Inc position peaked at $185K in Q3 2017.
  • 191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on Edge Wealth Management's 13F filing for Q4 2017, filed 18 Jan 2018.